Voltaren gastro-resistant tablets 25 mg No. 30

Voltaren gastro-resistant tablets are indicated for:

inflammatory and degenerative forms of rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis) pain syndromes of the spine; rheumatic diseases of extra-articular soft tissues; acute attacks of gout; post-traumatic and postoperative pain syndromes accompanied by inflammation and edema, for example, after dental and orthopedic interventions; gynecological diseases accompanied by pain syndrome and inflammation, for example, primary dysmenorrhea or adnexitis;

Composition

Active ingredient: diclofenac sodium;

1 gastro-resistant tablet contains diclofenac sodium 25 mg;

Excipients: colloidal silicon dioxide, microcrystalline cellulose, lactose monohydrate, magnesium stearate, corn starch, povidone K 30; sodium starch (type A);

Tablet coating: ipromellose (hydroxypropylmethylcellulose), polyethoxylated, hydrogenated castor oil, yellow iron oxide (E172), talc, titanium dioxide (E171);

Enteric-coated: methacrylate copolymer (type A), polyethylene glycol 8000 / macrogol 8000, silicone antifoam emulsion SE 2 / simethicone, talc.

Contraindication

Hypersensitivity to the active substance or to any of the other ingredients of the drug. Acute gastric or intestinal ulcer; gastrointestinal bleeding or perforation. History of gastrointestinal bleeding or perforation associated with previous treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). Active peptic ulcer/bleeding or history of recurrent peptic ulcer/bleeding. Last trimester of pregnancy. Inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis). Hepatic failure. Renal failure. Congestive heart failure (NYHA II-IV). Coronary heart disease in patients with angina or myocardial infarction. Cerebrovascular disease in patients with stroke or transient ischemic attacks. Peripheral arterial disease. Voltaren ®, like other nonsteroidal anti-inflammatory drugs, is contraindicated in patients who develop attacks of bronchial asthma, angioedema, urticaria or acute rhinitis, nasal polyps and other allergic symptoms in response to the use of ibuprofen, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

Method of application

The drug should be used in the most effective doses for the shortest period of time, taking into account the goal of treatment in each individual patient.

Application features

Pregnant women

It can only be prescribed when the expected benefit to the mother outweighs the potential risk to the fetus.

Children

From the age of 14.

Drivers

You should not drive or operate complex machinery.

Overdose

There is no typical clinical picture of diclofenac overdose. Overdose may cause symptoms such as headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhea, dizziness, disorientation, agitation, coma, drowsiness, tinnitus, or convulsions. Acute renal failure and liver damage are possible in severe intoxication.

Activated charcoal may be used after ingestion of potentially toxic doses, and gastric lavage (e.g., induction of vomiting, gastric lavage) may be performed after ingestion of potentially life-threatening doses.

Side effects

Nervous system: often - headache, dizziness. Hearing and labyrinth disorders: often - vertigo. Gastrointestinal tract: often - nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence. Skin and subcutaneous tissue disorders: often - rash. Kidneys and urinary system: often - fluid retention in the body, edema.

Interaction

Colestipol and cholestyramine. These drugs may delay or reduce the absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4-6 hours after colestipol/cholestyramine.

Cardiac glycosides. Concomitant use of cardiac glycosides and nonsteroidal anti-inflammatory drugs may exacerbate heart failure, reduce GFR, and increase plasma glycoside levels.

Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration, as NSAIDs may reduce the effect of mifepristone.

Storage conditions

Store at a temperature not exceeding 30 °C, protect from moisture.

Keep out of reach of children.

Shelf life - 3 years.